PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:	Atty. Docket No.: 01107.00193
KINZLER et al.	Prior Group Art Unit: 1632
Continuation of Application Serial No.: 08/390,474	Prior Examiner: S. Priebe
Filed: October 1, 2001	

For: **AMPLIFICATION OF MDM2 GENE OF HUMAN MDM2 GENE IN HUMAN TUMORS**

PRELIMINARY AMENDMENT

Assistant Commissioner of Patents
Washington, D. C. 20231

Sir:

Preliminarily to the examination of the above-identified application, kindly amend the application as follows:

IN THE SPECIFICATION:

Page 1, after the title, substitute the following paragraph:

This application is a continuation of U.S. Application Serial No. 08/390,474 filed February 17, 1995, which is a divisional of U.S. Application Serial No. 08/044,619, filed April 7, 1993, which is a continuation-in-part of U.S. Application Serial No. 07/903,103 filed June 23, 1992, which is a continuation-in-part of Application Serial No. 07/867,840, filed April 7, 1992, now abandoned.

<u>IN THE CLAIMS</u>:

27. (Amended) A method of treating a neoplastic cell, comprising:

administering to the cell a therapeutically effective amount of antisense oligonucleotides which are complementary to human MDM2 mRNA and which inhibit transcription or translation of a human MDM2 gene.

29. (Amended) A method of treating a neoplastic cell, comprising:

administering into the cell triple-strand forming oligonucleotides which bind to and are complementary to a human MDM2 gene and which inhibit transcription or translation of the human MDM2 gene.

56. (New) A method of treating a cell having an amplified human MDM2 gene, elevated expression of human MDM2 mRNA, or elevated expression of human MDM2 protein, comprising:

administering to the cell a therapeutically effective amount of antisense oligonucleotides which are complementary to human MDM2 mRNA and which inhibit transcription or translation of a human MDM2 gene.

57. (New) A method of treating a cell having an amplified human MDM2 gene, elevated expression of human MDM2 mRNA, or elevated expression of human MDM2 protein, comprising:

administering to the cell triple-strand forming oligonucleotides which bind to and are complementary to a human MDM2 gene and which inhibit transcription or translation of the human MDM2 gene.

58. (New) The method of claim 27 wherein the oligonucleotides are complementary to contiguous nucleotides selected from nucleotides 1-312 as shown in SEQ ID NO: 2.

59. (New) The method of claim 29 wherein the oligonucleotides are complementary to contiguous nucleotides selected from nucleotides 1-312 as shown in SEQ ID NO: 2.

60. (New) The method of claim 56 wherein the oligonucleotides are complementary to contiguous nucleotides selected from nucleotides 1-312 as shown in SEQ ID NO: 2.

61. (New) The method of claim 57 wherein the oligonucleotides are complementary to contiguous nucleotides selected from nucleotides 1-312 as shown in SEQ ID NO: 2.

REMARKS

The amendment to the specification is made in accordance with 35 U.S.C. 119, 37 C.F.R. 1.78 and 37 C.F.R. 1.55. The amendments to the claims are supported by page 10, last paragraph, by original claims 27-29, and by page 13, paragraph 2, which spans to page 14. No new matter has been entered. Entry is requested.

Respectfully submitted,

Dated: October 1, 2001

Sarah A. Kagan
Registration No. 32,141

BANNER & WITCOFF, LTD.
1001 G Street, N.W., 11th Floor
Washington, D.C. 20001
TEL: (202) 508-9100
FAX: (202) 508-9299

MARKED-UP VERSION

Page 1, after the title, substitute the following paragraph:

This application is a continuation of U.S. Application Serial No. 08/390,474, filed February 17, 1995, which is a divisional of U.S. Application Serial No. 08/044,619, filed April 7, 1993, which is a continuation-in-part of U.S. Application Serial No. ~~United States Serial No.~~ 07/903,103, filed June 23, 1992, which is a continuation-in-part of U.S. Application Serial ~~United States Serial~~ No. 07/867,840, filed April 7, 1992, now abandoned.

The claims have been amended as follows:

27. (Amended) A method of treating a neoplastic cell, comprising:

administering to the cell a therapeutically effective amount of [an inhibitory compound which] antisense oligonucleotides which are complementary to human MDM2 mRNA and which inhibit transcription or translation [interferes with the expression] of a human MDM2 gene.

29. (Amended) A [The] method of [claim 27 wherein expression of the human MDM2 gene is inhibited by] treating a neoplastic cell, comprising:

administering to the cell triple-strand forming oligonucleotides which [interact with DNA] bind to and are complementary to a human MDM2 gene and which inhibit transcription or translation of the human MDM2 gene.

56. (New) A method of treating a cell having an amplified human MDM2 gene, elevated expression of human MDM2 mRNA, or elevated expression of human MDM2 protein, comprising:

administering to the cell a therapeutically effective amount of antisense oligonucleotides which are complementary to human MDM2 mRNA and which inhibit transcription or translation of a human MDM2 gene.

57. (New) A method of treating a cell having an amplified human MDM2 gene, elevated expression of human MDM2 mRNA, or elevated expression of human MDM2 protein, comprising:

administering to the cell triple-strand forming oligonucleotides which bind to and are complementary to a human MDM2 gene and which inhibit transcription or translation of the human MDM2 gene.

62. (New) The method of claim 27 wherein the oligonucleotides are complementary to contiguous nucleotides selected from nucleotides 1-312 as shown in SEQ ID NO: 2.

63. (New) The method of claim 29 wherein the oligonucleotides are complementary to contiguous nucleotides selected from nucleotides 1-312 as shown in SEQ ID NO: 2.

64. (New) The method of claim 56 wherein the oligonucleotides are complementary to contiguous nucleotides selected from nucleotides 1-312 as shown in SEQ ID NO: 2.

65. (New) The method of claim 57 wherein the oligonucleotides are complementary to contiguous nucleotides selected from nucleotides 1-312 as shown in SEQ ID NO: 2.